Evidence map›Paper›PMID 41035406›Full record

ArticleHaematologica2026

HES1 regulates bone marrow mesenchymal stromal cell function by suppressing NFATc2-mediated inflammation.

Anthony Z Zhu, Zhilin Ma, Emily V Wolff, Sanghoon Lee, Zichen Lin, Zhenxia J Gao, Wei Du

Abstract read
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anthony Z ZhuDivision of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA.
Zhilin MaDepartment of Biological Sciences, University of Notre Dame, Notre Dame, IN.
Emily V WolffDivision of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Graduate Program, Pennsylvania State University School of Medicine, Hershey, PA.
Sanghoon LeeDivision of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA.
Zichen LinMaster of Science in Medical Science, Boston University School of Medicine Graduate Master Program, Boston, MA.
Zhenxia J GaoDivision of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA.
Wei DuDivision of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA. wed41@pitt.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
A beneficial persistent DNA damage-induced immune response in agingRF1AG093995 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DU, WEI · 2025 to 2025
$3.1M
Role of LAM-specific TREM1 in leukemogenesisR01CA285400 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Wei Du · 2024 to 2026
$2.6M
A novel immunometabolism-regulatory axis in inflammatory hematopoiesisR01HL151390 · NHLBI · WEST VIRGINIA UNIVERSITY · PI DU, WEI · 2020 to 2023
$1.5M
A beneficial persistent DNA damage-induced immune response in agingR56HL169348 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DU, WEI · 2024 to 2024
$710k
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA285400NHLBI NIH HHS R01 HL151390NHLBI NIH HHS R56 HL169348NIA NIH HHS RF1 AG093995
6 · The paper itself

Abstract

The Notch target gene, Hairy and enhancer of split-1 (HES1), encodes a basic helix-loop-helix transcriptional repressor that influences cell proliferation and differentiation in embryogenesis. Our previous studies indicate that HES1 is required for hematopoiesis under stress conditions. However, the role of HES1 in bone marrow (BM) microenvironment remains to be elucidated. By employing a BM niche specific Hes1 knockout mouse model, here we have investigated the role of HES1 in regulating mesenchymal stromal cell (MSC) homeostasis and their hematopoiesis supportive function. We found that while HES1 is not essential in MSC in supporting steady-state hematopoiesis, Hes1fl/flPrx1Cre mice are hypersensitive to lipopolysaccharide (LPS) challenge. Deletion of Hes1 in the BM reduces MSC frequency and affects MSC self-renewal and proliferation. Hes1-deficient MSC are less functional in supporting hematopoiesis both in vitro and ex vivo. Transcriptome analysis reveals that disruption of Hes1 in the BM stroma alters the expression of genes critical for cellular metabolism and inflammation. Pharmacological blockage of inflammation rescues Hes1-KO MSC phenotype and improves their hematopoiesis supportive function. Mechanistically, we show that HES1 binds to the conserved E boxes in the promoter of NFATc2, a member of the AT-rich interaction domain superfamily of DNA binding protein, to suppress NFATc2-mediated inflammation. Taken together, our study unveils a pivotal role for HES1 in maintaining BM MSC hemostasis and regulating their hematopoiesis supportive function.

Indexed as

Bone Marrow CellsInflammationMesenchymal Stem CellsNFATC Transcription FactorsTranscription Factor HES-1AnimalsCell ProliferationHematopoiesisMiceMice, KnockoutHes1 protein, mouseNfatc2 protein, mouseNFATC Transcription FactorsTranscription Factor HES-1

Identifiers

PMID41035406
PMCPMC13040167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.